Also, Tasly Biopharmaceuticals, a biopharma unit of Shanghai-listed Tasly Pharmaceutical Group, plans to raise about US$500 million from a Hong Kong IPO, according to Reuters IFR. Meanwhile, Ernst & …
( read original story …)
The HongKong News
Also, Tasly Biopharmaceuticals, a biopharma unit of Shanghai-listed Tasly Pharmaceutical Group, plans to raise about US$500 million from a Hong Kong IPO, according to Reuters IFR. Meanwhile, Ernst & …
( read original story …)